补充因子H 是一个ICOS连接体,在质瘤微环境中调节Tregs
Karolina I Smolag1, Jakub Olszowka1, Rebecca Rosberg2
1Section of Medical Protein Chemistry, Department of Translational Medicine, Lund University, Malmö, Sweden.
Cancer immunology research
|October 8, 2024
概括
补充因子H (FH) 在质瘤中促进调节性T细胞 (Treg) 的存活和功能,导致免疫抑制性瘤微环境和更差的患者预后. 评估FH可以预测免疫疗法反应.
科学领域:
- 神经瘤学神经瘤学
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 尽管免疫疗法取得了进展,但质瘤存活率仍然很低,部分原因是免疫抑制性瘤微环境.
- 调控性T细胞 (Tregs) 是质瘤微环境中的免疫耐受性的关键调解者.
研究的目的:
- 调查补充因子H (FH) 在调节质瘤微环境中的Tregs中的作用.
- 为了确定FH对Treg功能,质瘤进展和患者预后的影响.
主要方法:
- 研究FH作为ICOS配体及其对Treg生存,功能和细胞因子分泌 (TGFβ,IL10) 的影响.
- 在人类和小鼠样本中评估了质瘤细胞的FH产生.
- 通过使用数据库调查,分析了与Treg存在和患者预后有关的FH表达.
- 利用小鼠质瘤模型来评估FH敲击对Tregs和生存的体内效应.
主要成果:
- FH被确定为一种ICOS配体,增强Treg生存和功能,促进免疫抑制.
- FH诱导Tregs分泌TGFβ和IL10,抑制T细胞的增殖.
- 发现质瘤细胞直接产生FH.
- 升高的FH表达与Treg存在增加和质瘤患者预后较差相关.
- 在小鼠模型中,FH敲击降低了ICOS+Tregs,并显示了延长生存的趋势.
结论:
- 通过促进Treg积累和功能,FH在促进免疫抑制性质瘤微环境方面发挥着关键作用.
- FH是预测质瘤预后和免疫治疗反应的潜在生物标志物.
- 向FH或Tregs可能是质瘤的新疗法策略.
相关概念视频
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K
The Tumor Microenvironment
6.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.6K
T Cell Types and Functions
959
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
959
Tumor Immunotherapy
488
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
488


